证券代码：A 股 600613 股票简称：A 股 神奇制药 编号：2025-029 B 股 900904 B 股 神奇 B 股 1．主营业务分行业情况 单位：元 1 分行业 2025年 1-6月营业 收入 2025 年 1-6 月营 业成本 毛利率 （%） 营业收 入比上 期增减 （%） 营业成 本比上 期增减 （%） 毛利率 比上年 增减百 分点 一、医药制造 551,106,207.88 145,299,577.01 73.63 -17.88 -22.39 1.53 二、医药商业 409,743,638.84 365,475,382.80 10.80 -6.73 -7.94 1.17 合计 960,849,846.72 510,774,959.81 46.84 -13.47 -12.57 -0.54 2．主营业务分类情况 单位：元 分产品 营业收入 营业成本 毛利率 （%） 营业收入 比上年增 减（%） 营业成本 比上年增 减（%） 毛利率 比上年 增减百 分点 抗肿瘤药系列 245,469,455.95 27,664,258.77 88.73 -6.54 -13.13 0.85 皮肤外用抗菌 系列 58 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.12% on August 29, with RunDa Medical leading the drop [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Stock Performance - Baiyang Pharmaceutical (301015) saw a significant increase of 6.58%, closing at 26.40 with a trading volume of 183,800 shares and a transaction value of 479 million [1] - Other notable gainers included Jianzhijia (605266) with a 3.05% increase, and Yingte Group (000411) with a 2.65% increase [1] - Conversely, RunDa Medical (603108) declined by 2.17%, closing at 17.57 with a trading volume of 237,400 shares [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 300 million in main funds, while retail investors saw a net inflow of 214 million [2] - The sector's capital flow indicates that while institutional investors withdrew funds, retail investors were actively buying [2] Individual Stock Capital Flow - SaiLi Medical (603716) had a main fund net inflow of 97.15 million, but saw a net outflow from retail investors of 56.18 million [3] - YiXinTang (002727) experienced a net inflow of 5.04 million from main funds, while retail investors had a slight outflow of 0.67 million [3] - Nanjing Medical (600713) had a net inflow of 2.51 million from main funds, with retail investors experiencing a net outflow of 5.07 million [3]

人民财讯8月29日电，南京医药（600713）8月29日晚间披露半年报，2025年上半年，公司实现营业收入 279.67亿元，同比增长2.7%；归属于上市公司股东的净利润2.91亿元，同比下降6.44%；基本每股收益 0.222元。公司拟向全体股东每10股派发现金红利1.7元(含税)。 (资料图片仅供参考) ...

格隆汇8月29日丨南京医药(600713.SH)公布2025年半年度报告，报告期实现营业收入279.67亿元，同比 增长2.70%；归属于上市公司股东的净利润2.91亿元，同比下降6.44%；归属于上市公司股东的扣除非经 常性损益的净利润2.66亿元，同比下降14.08%；基本每股收益0.222元。 ...

南京医药公告，2025年上半年营业收入279.67亿元，同比增长2.70%。净利润2.91亿元，同比下降 6.44%。 ...

格隆汇8月29日｜A股三大指数8月份齐收涨，且均录得月线4连涨；其中，沪指涨7.97%报3857点，月内接连突破3700点、3800点关口；深证成指涨15.32%报 12696点，创业板指涨24.13%报2890点一度站上2900点。 MACD金叉信号形成，这些股涨势不错！ 个股方面，8月涨幅前五的个股为：广东建科涨415.55%、能之光涨309.57%、宏远股份涨261.61%、酉立智能涨231.97%、志高机械涨191.56%；同期，跌幅 前五的个股为：*ST高鸿（维权）跌51.64%、花蓝集团跌31.65%、ST应急（维权）跌27.98%、韩建河山跌26.88%、幸福蓝海跌26.7%。(格隆汇) 板块方面，近20个交易日涨幅前五的板块为：小金属涨25.12%、其他电源设备涨21.98%、通信设备涨21.72%、消费电子涨20.31%、半导体涨19.27%；同 期，跌幅前五的板块为：医药商业跌2.85%、中药跌2.79%、化学制药跌2.02%、银行跌1.65%、公路铁路运输跌0.21%。 ...

证券之星消息，8月28日，国药股份（600511）融资买入1867.42万元，融资偿还1857.51万元，融资净买 入9.91万元，融资余额3.42亿元，近3个交易日已连续净买入累计1188.33万元，近20个交易日中有15个 交易日出现融资净买入。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-28 | 9.91万 | 3.42亿 | 2.08% | | 2025-08-27 | 527.02万 | 3.42 乙 | 2.07% | | 2025-08-26 | 651.40万 | 3.37亿 | 2.00% | | 2025-08-25 | 280.55万 | 3.31亿 | 1.96% | | 2025-08-22 | -130.60万 | 3.28亿 | 1.96% | 融券方面，当日融券卖出8600.0股，融券偿还1600.0股，融券净卖出7000.0股，融券余量22.61万股，近3 个交易日已连续净卖出累计4.55万股，近20个交易日中有12个交易日出现融券净卖出。 | 交易日 | 两融余额（元） ...

Core Points - The company has decided not to distribute cash dividends or issue bonus shares for the reporting period [3] - The company has completed the "Dajia Weikang Pharmaceutical Industry Base Project," which significantly enhances its storage, sorting, and logistics capabilities, thereby strengthening its competitive position in the pharmaceutical industry [5] - The company approved a profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 0.818 per 10 shares, totaling RMB 16,801,981.76 [6] Company Overview - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5] - The company has no preferred shareholders or related shareholding changes during the reporting period [5] Important Matters - The company held a board meeting on August 27, 2025, to approve adjustments to the prices related to the 2023 restricted stock and stock option incentive plan [8] - The adjusted price for the second category of restricted stock is set at RMB 6.7582 per share, down from RMB 6.7982 per share, while the stock option exercise price is adjusted to RMB 13.6382 per share from RMB 13.6782 per share [7][12] Impact of Adjustments - The adjustments to the incentive plan prices comply with relevant regulations and will not materially affect the company's financial status or operational results [14] - The company's remuneration and assessment committee supports the adjustments, confirming that the process is legal and compliant [15]

Core Viewpoint - The financial report of Yingte Group for the first half of 2025 shows a slight increase in revenue but a decline in net profit, indicating a challenging financial environment for the company [1]. Financial Performance Summary - Total operating revenue reached 16.628 billion yuan, a year-on-year increase of 0.11% [1]. - Net profit attributable to shareholders was 249 million yuan, a decrease of 3.45% year-on-year [1]. - In Q2 2025, operating revenue was 8.192 billion yuan, up 2.23% year-on-year, while net profit was 148 million yuan, down 1.85% [1]. - Gross margin stood at 6.66%, down 1.34% year-on-year, and net margin was 1.73%, down 4.89% [1]. - Total expenses (selling, administrative, and financial) amounted to 652 million yuan, accounting for 3.92% of revenue, a decrease of 4.03% year-on-year [1]. - Earnings per share were 0.48 yuan, down 4.0% year-on-year, and operating cash flow per share was -1.34 yuan, a decrease of 18.13% [1]. Business Model and Operational Insights - The company's performance is primarily driven by marketing efforts, necessitating a thorough examination of the underlying factors behind this drive [2]. - Historical data indicates a median Return on Invested Capital (ROIC) of 8.98% over the past decade, suggesting average capital returns [1]. - The company has reported three years of losses since its listing, indicating a fragile business model [1]. Cash Flow and Debt Analysis - The cash flow situation is concerning, with cash and cash equivalents to current liabilities at only 29.5%, and the average operating cash flow over the past three years to current liabilities at 6.72% [3]. - The interest-bearing debt ratio has reached 23.59%, highlighting potential debt management issues [3]. - Accounts receivable have reached 1398.64% of profit, indicating a significant concern regarding receivables management [3]. Fund Holdings - The largest fund holding shares in Yingte Group is the Wanji Quantitative Tongshun Multi-Strategy Mixed A fund, which has recently increased its position [4]. - The fund's current scale is 28 million yuan, with a recent net value increase of 0.62% and a yearly increase of 53.08% [4].

Financial Performance - China Medical's net profit decreased by 16.19% year-on-year, with total revenue of 17.076 billion yuan, down 6.71% [1] - For Q2, total revenue was 8.813 billion yuan, a decline of 7.51%, and net profit was 128 million yuan, down 37.81% [1] - Gross margin was 10.43%, a decrease of 4.3%, while net margin was 2.2%, down 15.35% [1] - Total expenses (selling, administrative, and financial) amounted to 1.025 billion yuan, accounting for 6.0% of revenue, a decrease of 9.92% [1] Key Financial Ratios - Earnings per share (EPS) was 0.20 yuan, down 16.2% year-on-year [1] - Return on Invested Capital (ROIC) for the previous year was 4.27%, indicating weak capital returns [3] - The historical median ROIC over the past decade was 9.52%, suggesting average investment returns [3] Cash Flow and Receivables - Cash flow per share was -0.37 yuan, an increase of 26.5% year-on-year [1] - The ratio of cash and cash equivalents to current liabilities was only 26.34%, indicating potential liquidity concerns [4] - Accounts receivable reached 2756.59% of profit, raising concerns about collection efficiency [4]